Intracellular signals coupled to different rat ileal muscarinic receptor subtypes

Cellular Signalling

Volumn 9, Issue 5, 1997, Pages 373-378

  Sales, Maria Elena ^a   Sterin Borda, Leonor ^a   Rodriguez, Martin ^a   Borda, Enri S ^a  

^a Centre de Estudios Farmacologicos y Botanicos   (Argentina)

Author keywords

cAMP; cGMP; Ileal contractility; Muscarinic receptors; Phosphoinositide hydrolysis; Rat ileum

Indexed keywords

ATROPINE; ISOPRENALINE; MEMBRANE RECEPTOR; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; QUINUCLIDINYL BENZILATE; RECEPTOR SUBTYPE; TRITIUM;

ANIMAL CELL; ARTICLE; CELL COMMUNICATION; COMPETITIVE INHIBITION; DISSOCIATION CONSTANT; DRUG RECEPTOR BINDING; ELECTROLYTE TRANSPORT; ILEUM; INTESTINE FUNCTION; INTESTINE MOTILITY; ISOTOPE LABELING; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

ANIMALS; CELL MEMBRANE; CYCLIC AMP; CYCLIC GMP; ENZYME ACTIVATION; ILEUM; INOSITOL PHOSPHATES; KINETICS; MUSCARINIC ANTAGONISTS; QUINUCLIDINYL BENZILATE; RATS; RECEPTORS, MUSCARINIC; REGRESSION ANALYSIS; SIGNAL TRANSDUCTION;

ANIMALIA; TRITIUM;

EID: 0030765310     PISSN: 08986568     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0898-6568(96)00194-5     Document Type: Article

References (24)

1. Eglen R. M., Reddy H, Watson N. and Challis R. A. J. (1994) Trends Pharmacol. Sci. 176, 114-119.
2. Giraldo E. F., Monferini H., Ladinsky J. and Hammer R. (1987) Eur. J. Pharmacol. 141, 475-477.
3. Zhang L., Horowitz B. and Buxton I. L. O. (1991) Mol. Pharmacol. 40, 943-951.
4. Doods H. N., Willim K. D., Boddlike H. W. G. M. and Entzeroth M. (1993) Eur. J. Pharmacol. 250, 223-230.
5. Berridge M. J. (1975) Adv. Cyclic Nucleotides Res. 6, 1098-1101.
6. Zhang L. and Buxton I. L. O. (1991) Mol. Pharmacol. 40, 952-959.
7. Challiss R. A. J., Adams D., Mistry R. and Boyle J. P. (1993) Biochem. Soc. Trans. 21, 1138-1143.
8. Kachur J. F., Sturm B. L., Gaginella T. S. and Noronha-Blob L. (1990) Mol. Pharmacol. 38, 836-840.
9. de Bracco M. M. E., Borda E., Galassi N, Pérez Bianco R. and Sterin-Borda L. (1993) Autoimmunity, 14, 307-314.
10. Berridge M. J., Downes C. P. and Hanley M. P. (1982) Biochem. J. 206, 587-595.
11. Camusso J. J., Sterin-Borda L., Rodriguez M., Bacman S. and Borda E. (1995) J. Lipid Mediators Cell. Signalling 12, 1-10.
12. Brown B. L., Albano J. D. M., Ekins R. P. and Sgherzi A. M. (1971) Biochem. J. 121, 561-562.
13. Munson J. and Rodbard D. (1980) Anal. Biochem. 107, 220-239.
14. Watson M., Roeske W. R. and Yamamura H. I. (1986) Trends Pharmacol. Sci. 237, 419-427.
15. Hammer R., Giraldo E., Schiavi G. B., Monferini E. and Sadinsky H. (1986) Life Sci. 38, 1653-1662.
16. Gies J. P., Bertrand C., Vanderheyden P., Waeldele F., Dumont P., Pauli G. and Landry Y. (1989) Mol. Pharmacol. 250, 309-315.
17. Lucchesi P. A., Scheid C. R., Romano F. D., Kargain M. E., Mullikin-Kilpatrick D., Yamaguchi H. and Honeyman T. W. (1990) Am. J. Physiol. 258, C730-C738.
18. Buckley N. J., Bonner T. I., Buckley C. M. and Brann M. R. (1989) Mol. Pharmacol. 35, 469-176.
19. Haddad E. B., Landry Y. and Gies J. P. (1991) Am. J. Physiol. 261, L327-L333.
20. Hulme E.C., Birdsall N. J. M. and Buckley N.J. (1990) Annu. Rev. Pharmacol. Toxicol. 30, 633-673.
21. Doods H. N., Matley M. J., Davidesko D., Van Charldorp K. J., de Jorge A. and Van Zwieten P. A. (1987) J. Pharmacol. Exp. Ther. 242, 257-262.
22. Eglen R. M. and Harris G. C. (1993) Mol. Pharmacol. 109, 946-952.
23. Watson N. and Eglen R. M. (1994) Br. J. Pharmacol. 112, 170-187.
24. Schmidt H. H. H. W., Sfeifer R. and Böhme E. (1989) FEBS Letters 244, 357-360.